Factor Xa inhibitors, rivaroxaban, apixaban, and edoxaban, have demonstrated non‐inferiority or superiority to warfarin in the prevention of stroke and systemic embolism in randomized clinical trials (RCTs) [4, 5, 6]. Here, F10 is linked to Stroke.